Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.50 |
| ▸ | GLUL | P15104 | 1/20 | 0.44 |
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499841 | 0.78 | ALDH1A1 (0.57) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9788135 | 0.78 | OTC (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8935175 | 0.76 | METAP1 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12648443 | 0.75 | GLUL (0.70) | GLULBHMTGRM8GRM6GRM7 | |
| SCHEMBL56139 | 0.75 | GLUL (0.70) | GLULBHMTGRM8GRM6GRM7 | |
| SCHEMBL1969235 | 0.75 | GLUL (0.70) | GLULBHMTGRM8GRM6GRM7 | |
| SCHEMBL31230376 | 0.75 | GLUL (0.70) | GLULBHMTGRM8GRM6GRM7 | |
| Water SCHEMBL21747423 | 0.73 | GLUL (0.68) | GLULBHMTGRM8GRM6GRM7 | |
| Water SCHEMBL21747433 | 0.73 | GLUL (0.68) | GLULBHMTGRM8GRM6GRM7 | |
| Water SCHEMBL21747432 | 0.73 | GLUL (0.68) | GLULBHMTGRM8GRM6GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-5834465-A | FOR PROTECTING BRAIN AGAINST ACUTE DAMAGE IN STROKE, EPILEPSY, TRAUMA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | claimed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| WO-1996040155-A1 | USE OF SPECIFIC ACPA DERIVATIVE (NPC-17742) FOR THE TREATMENT OF ISCHEMIA | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0639197-B1 | EXCITATORY AMINO ACID ANTAGONISTS | GUILFORD PHARM INC (US) | 1996-09-04 | — | — | EP | claimed |
| EP-0639197-A1 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0639197-A4 | EXCITATORY AMINO ACID ANTAGONISTS. | GUILFORD PHARM INC (US) | 1994-02-21 | — | — | EP | claimed |
| US-5256814-A | Anticonvulsant, analgesic, cognition activator | SCIOS NOVA INC. (US) | 1993-10-26 | — | — | US | claimed |
| WO-1992010099-A1 | EXCITATORY AMINO ACID ANTAGONISTS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-06-25 | — | — | WO | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| US-5049555-A | Central nervous system | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-09-17 | — | — | US | claimed |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | STUART L. WEG | 2022-02-24 | — | — | US | disclosed |
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-1992010099-A1 | EXCITATORY AMINO ACID ANTAGONISTS | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | disclosed |
| US-5049555-A | Central nervous system | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | GRIN2D 9/4885GRIN3B 7/4885GRIN1 5/4885 |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | GRIN2D 9/4885GRIN3B 7/4885GRIN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.